Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma

Background and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumo...

Full description

Bibliographic Details
Main Authors: Samuel Early, Charlotte E. Rinnooy Kan, Maura Eggink, Johan H. M. Frijns, Konstantina M. Stankovic
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.00796/full
id doaj-18c9235969414559830b48370e4ec83c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Samuel Early
Samuel Early
Samuel Early
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Maura Eggink
Maura Eggink
Maura Eggink
Johan H. M. Frijns
Johan H. M. Frijns
Johan H. M. Frijns
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
spellingShingle Samuel Early
Samuel Early
Samuel Early
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Maura Eggink
Maura Eggink
Maura Eggink
Johan H. M. Frijns
Johan H. M. Frijns
Johan H. M. Frijns
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
Frontiers in Neurology
vestibular schwannoma
hearing loss
contralateral
secreted factors
outcomes
author_facet Samuel Early
Samuel Early
Samuel Early
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Charlotte E. Rinnooy Kan
Maura Eggink
Maura Eggink
Maura Eggink
Johan H. M. Frijns
Johan H. M. Frijns
Johan H. M. Frijns
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
Konstantina M. Stankovic
author_sort Samuel Early
title Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
title_short Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
title_full Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
title_fullStr Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
title_full_unstemmed Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular Schwannoma
title_sort progression of contralateral hearing loss in patients with sporadic vestibular schwannoma
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2020-08-01
description Background and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumor factors, in addition to mechanical compression of the adjacent auditory nerve, and these factors may percolate through CSF or blood to affect contralateral hearing as well.Methods: This is a retrospective study of medical records for patients treated for VS at Mass Eye and Ear from January 1994 through October 2018. Included patients had unilateral VS and sequential audiometry allowing for longitudinal assessment of hearing over time. Mass Eye and Ear's audiology database was used to select age- and sex-matched case controls, also with sequential audiometry, from the non-VS population. Subgroup analysis was performed by age, sex, baseline hearing, and tumor size at initial diagnosis. Hearing loss progression was performed using Kaplan-Meier analysis to account for variable follow-up times.Results: A total of 661 patients were identified with VS and sequential audiometry. The population was predominantly female vs. male (368 vs. 293, p = 0.0035), driven primarily by younger patients with Koos 4 tumors (76 female vs. 49 male, p = 0.016). Patients with normal baseline hearing bilaterally (N = 241) demonstrated no significant difference in hearing loss progression in VS-contralateral vs. control ears. Patients with abnormal baseline VS-ipsilateral hearing (N = 190), however, demonstrated significantly higher likelihood of reaching moderate SNHL in VS-contralateral ears. Subgroup analysis by age, sex, and baseline tumor size did not yield any subgroup-specific trends for hearing loss progression.Discussion and Conclusion: This is the largest study to date tracking long-term bilateral hearing outcomes in patients with VS, and demonstrates that, in patients with abnormal hearing in the VS-ipsilateral ear, there exists a long-term risk of progression to moderate hearing loss in the contralateral ear as well. Combined with the absence of significant changes in word understanding in the affected ears, these findings may provide clues to the nature of tumor-secreted factors involved in VS-associated hearing loss. Female predominance within the VS patient population is confirmed, driven mostly by younger female patients with Koos 4 tumors.
topic vestibular schwannoma
hearing loss
contralateral
secreted factors
outcomes
url https://www.frontiersin.org/article/10.3389/fneur.2020.00796/full
work_keys_str_mv AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT samuelearly progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT charlotteerinnooykan progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT mauraeggink progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT johanhmfrijns progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
AT konstantinamstankovic progressionofcontralateralhearinglossinpatientswithsporadicvestibularschwannoma
_version_ 1724604150594928640
spelling doaj-18c9235969414559830b48370e4ec83c2020-11-25T03:23:59ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-08-011110.3389/fneur.2020.00796549971Progression of Contralateral Hearing Loss in Patients With Sporadic Vestibular SchwannomaSamuel Early0Samuel Early1Samuel Early2Charlotte E. Rinnooy Kan3Charlotte E. Rinnooy Kan4Charlotte E. Rinnooy Kan5Maura Eggink6Maura Eggink7Maura Eggink8Johan H. M. Frijns9Johan H. M. Frijns10Johan H. M. Frijns11Konstantina M. Stankovic12Konstantina M. Stankovic13Konstantina M. Stankovic14Konstantina M. Stankovic15Eaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesSan Diego School of Medicine, University of California, San Diego, San Diego, CA, United StatesEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesLeiden University Medical Center, Leiden, NetherlandsEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesUniversity Medical Center Groningen, Groningen, NetherlandsLeiden University Medical Center, Leiden, NetherlandsDepartment of Otolaryngology—Head and Neck Surgery, Leiden University Medical Center, Leiden, NetherlandsLeiden Institute for Brain and Cognition, Leiden, NetherlandsEaton-Peabody Laboratories, Department of Otolaryngology—Head and Neck Surgery, Massachusetts Eye and Ear, Boston, MA, United StatesDepartment of Otolaryngology—Head and Neck Surgery, Harvard Medical School, Boston, MA, United StatesProgram in Speech and Hearing Bioscience and Technology, Harvard Medical School, Boston, MA, United StatesHarvard Program in Therapeutic Science, Harvard Medical School, Boston, MA, United StatesBackground and Introduction: Vestibular schwannomas (VSs) are the most common tumors of the cerebellopontine angle, typically presenting unilaterally with ipsilateral sensorineural hearing loss (SNHL). The mechanism of tumor-induced hearing loss has recently been shown to be related to secreted tumor factors, in addition to mechanical compression of the adjacent auditory nerve, and these factors may percolate through CSF or blood to affect contralateral hearing as well.Methods: This is a retrospective study of medical records for patients treated for VS at Mass Eye and Ear from January 1994 through October 2018. Included patients had unilateral VS and sequential audiometry allowing for longitudinal assessment of hearing over time. Mass Eye and Ear's audiology database was used to select age- and sex-matched case controls, also with sequential audiometry, from the non-VS population. Subgroup analysis was performed by age, sex, baseline hearing, and tumor size at initial diagnosis. Hearing loss progression was performed using Kaplan-Meier analysis to account for variable follow-up times.Results: A total of 661 patients were identified with VS and sequential audiometry. The population was predominantly female vs. male (368 vs. 293, p = 0.0035), driven primarily by younger patients with Koos 4 tumors (76 female vs. 49 male, p = 0.016). Patients with normal baseline hearing bilaterally (N = 241) demonstrated no significant difference in hearing loss progression in VS-contralateral vs. control ears. Patients with abnormal baseline VS-ipsilateral hearing (N = 190), however, demonstrated significantly higher likelihood of reaching moderate SNHL in VS-contralateral ears. Subgroup analysis by age, sex, and baseline tumor size did not yield any subgroup-specific trends for hearing loss progression.Discussion and Conclusion: This is the largest study to date tracking long-term bilateral hearing outcomes in patients with VS, and demonstrates that, in patients with abnormal hearing in the VS-ipsilateral ear, there exists a long-term risk of progression to moderate hearing loss in the contralateral ear as well. Combined with the absence of significant changes in word understanding in the affected ears, these findings may provide clues to the nature of tumor-secreted factors involved in VS-associated hearing loss. Female predominance within the VS patient population is confirmed, driven mostly by younger female patients with Koos 4 tumors.https://www.frontiersin.org/article/10.3389/fneur.2020.00796/fullvestibular schwannomahearing losscontralateralsecreted factorsoutcomes